bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figures from Aberrant JMJD3 Expression Upregulates Slug to Promote Migration, Invasion, and Stem Cell–Like Behaviors in Hepatocellular Carcinoma
Authors: Tang Bo , Qi Guangying , Tang Fang , Yuan Shengguang , Wang Zhenran , Liang Xingsi , Li Bo , Yu Shuiping , Liu Jie , Huang Qi , Wei Yangchao , Zhai Run , Lei Biao , Yu Hongping , Tomlinson Stephen , He Songqing
Published: April 2023

This file contains 10 supplemental figures. Supplemental Figure 1. JMJD3 is highly expressed in HCC tissues and cancer cell lines. Supplemental Figure 2. JMJD3 promotes proliferative capacity of HCC cells both in vivo. Supplemental Figure 3. JMJD3 promotes proliferative, EMT, migratory, and invasive capacities of HCC cells. Supplemental Figure. 4 JMJD3 promotes emergence of stem cell-like behavior in HCC cells. Supplemental Figure. 5 JMJD3 promotes emergence of stem cell-like behavior in HCC cells. Supplemental Figure. 6 JMJD3 regulates slug expression need its demethylase activity. Supplemental Figure. 7 JMJD3 regulates slug expression through H3K27 trimethylation Supplemental Figure. 8 JMJD3 regulates slug expression through H3K27 trimethylation Supplemental Figure. 9 Slug is a mediator for JMJD3-induced migration, invasion and in vivo metastasis capacity in HCC cells. Supplemental Figure. 10 Slug is a mediator for JMJD3-induced stemness capacity in HCC cells.
Supplementary Table S1 from Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging
Authors: Tromberg Bruce J. , Zhang Zheng , Leproux Anaïs , O'Sullivan Thomas D. , Cerussi Albert E. , Carpenter Philip M. , Mehta Rita S. , Roblyer Darren , Yang Wei , Paulsen Keith D. , Pogue Brian W. , Jiang Shudong , Kaufman Peter A. , Yodh Arjun G. , Chung So Hyun , Schnall Mitchell , Snyder Bradley S. , Hylton Nola , Boas David A. , Carp Stefan A. , Isakoff Steven J. , Mankoff David
Published: April 2023

Accrual table by institution.
Supplementary Methods from Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging
Authors: Tromberg Bruce J. , Zhang Zheng , Leproux Anaïs , O'Sullivan Thomas D. , Cerussi Albert E. , Carpenter Philip M. , Mehta Rita S. , Roblyer Darren , Yang Wei , Paulsen Keith D. , Pogue Brian W. , Jiang Shudong , Kaufman Peter A. , Yodh Arjun G. , Chung So Hyun , Schnall Mitchell , Snyder Bradley S. , Hylton Nola , Boas David A. , Carp Stefan A. , Isakoff Steven J. , Mankoff David
Published: April 2023

List of Chemotherapy regimens used in this study.
Supplementary Figure 1 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors
Authors: Shukla Neerav , Somwar Romel , Smith Roger S. , Ambati Sri , Munoz Stanley , Merchant Melinda , D'Arcy Padraig , Wang Xin , Kobos Rachel , Antczak Christophe , Bhinder Bhavneet , Shum David , Radu Constantin , Yang Guangbin , Taylor Barry S. , Ng Charlotte K.Y. , Weigelt Britta , Khodos Inna , de Stanchina Elisa , Reis-Filho Jorge S. , Ouerfelli Ouathek , Linder Stig , Djaballah Hakim , Ladanyi Marc
Published: April 2023

A. Pairâ€�wise expression profile comparisons of EWS cell lines treated with the known proteasome inhibitors bortezomib and MGâ€�262 demonstrated highly significant overlap with profiles treated with compounds EWS-P and EWS-W. B. Overlap included 13 core genes established through published studies as being upregulated by 20S inhibitors such as bortezomib and MG-262. C. EWS cell lines TC-71 and CHP100 show demonstrate an increase in polyubiquitinated proteins following treatment with proteasome inhibitors MG-262, bortezomib, EWS-P, and EWS-W.
Table S1 from Individualized Breast Cancer Characterization through Single-Cell Analysis of Tumor and Adjacent Normal Cells
Authors: Anjanappa Manjushree , Cardoso Angelo , Cheng Lijun , Mohamad Safa , Gunawan Andrea , Rice Susan , Dong Yan , Li Lang , Sandusky George E. , Srour Edward F. , Nakshatri Harikrishna
Published: April 2023

Gene expression patterns in tumor and normal cells of three patients with statistical analyses
Figure S6 from Individualized Breast Cancer Characterization through Single-Cell Analysis of Tumor and Adjacent Normal Cells
Authors: Anjanappa Manjushree , Cardoso Angelo , Cheng Lijun , Mohamad Safa , Gunawan Andrea , Rice Susan , Dong Yan , Li Lang , Sandusky George E. , Srour Edward F. , Nakshatri Harikrishna
Published: April 2023

Figure S6 shows MMP2 expression pattern in tumor and adjacent normal breast tissue
Figure S5 from Individualized Breast Cancer Characterization through Single-Cell Analysis of Tumor and Adjacent Normal Cells
Authors: Anjanappa Manjushree , Cardoso Angelo , Cheng Lijun , Mohamad Safa , Gunawan Andrea , Rice Susan , Dong Yan , Li Lang , Sandusky George E. , Srour Edward F. , Nakshatri Harikrishna
Published: April 2023

Figure S5 shows unsupervised clustering of stemless genes in all cell types examined in patient 2
Supplementary Methods from EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells
Authors: Bai Shoumei , Ingram Patrick , Chen Yu-Chih , Deng Ning , Pearson Alex , Niknafs Yashar S. , O'Hayer Patrick , Wang Yun , Zhang Zhong-Yin , Boscolo Elisa , Bischoff Joyce , Yoon Euisik , Buckanovich Ronald J.
Published: April 2023

Supplementary Methods
Figure S4 from Individualized Breast Cancer Characterization through Single-Cell Analysis of Tumor and Adjacent Normal Cells
Authors: Anjanappa Manjushree , Cardoso Angelo , Cheng Lijun , Mohamad Safa , Gunawan Andrea , Rice Susan , Dong Yan , Li Lang , Sandusky George E. , Srour Edward F. , Nakshatri Harikrishna
Published: April 2023

Figure S4 shows unsupervised clustering of PAM50 genes examined in all cells of patient 2
Supplementary Figures 1-8 from EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells
Authors: Bai Shoumei , Ingram Patrick , Chen Yu-Chih , Deng Ning , Pearson Alex , Niknafs Yashar S. , O'Hayer Patrick , Wang Yun , Zhang Zhong-Yin , Boscolo Elisa , Bischoff Joyce , Yoon Euisik , Buckanovich Ronald J.
Published: April 2023

Supplementary Figures 1-8
Supporting Information from Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging
Authors: Sans Marta , Gharpure Kshipra , Tibshirani Robert , Zhang Jialing , Liang Li , Liu Jinsong , Young Jonathan H. , Dood Robert L. , Sood Anil K. , Eberlin Livia S.
Published: April 2023

The supporting information file contains figures with experimental data such as tandem mass spectrometry mass spectra, 2D ion images, representative mass spectra of cancer and normal tissues, and mass spectra of standard compounds. Tables are also included which present identification of molecular markers, and predictive accuracy results for the molecular models.
Supplemental Figure 6 from An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma
Authors: Silva Ariosto , Silva Maria C. , Sudalagunta Praneeth , Distler Allison , Jacobson Timothy , Collins Aunshka , Nguyen Tuan , Song Jinming , Chen Dung-Tsa , Chen Lu , Cubitt Christopher , Baz Rachid , Perez Lia , Rebatchouk Dmitri , Dalton William , Greene James , Gatenby Robert , Gillies Robert , Sontag Eduardo , Meads Mark B. , Shain Kenneth H.
Published: April 2023

Individual patient EMMA predicitons of actual responses to therapy (companion to Figure 3i).
Supplementary Methods from Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment
Authors: Gomez-Chou Sobeyda B. , Swidnicka-Siergiejko Agnieszka Katarzyna , Badi Niharika , Chavez-Tomar Myrriah , Lesinski Gregory B. , Bekaii-Saab Tanios , Farren Matthew R. , Mace Thomas A. , Schmidt Carl , Liu Yan , Deng Defeng , Hwang Rosa F. , Zhou Liran , Moore Todd , Chatterjee Deyali , Wang Huamin , Leng Xiaohong , Arlinghaus Ralph B. , Logsdon Craig D. , Cruz-Monserrate Zobeida
Published: April 2023

Additional Experimental Methods
Supplemental Table 1 from Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment
Authors: Gomez-Chou Sobeyda B. , Swidnicka-Siergiejko Agnieszka Katarzyna , Badi Niharika , Chavez-Tomar Myrriah , Lesinski Gregory B. , Bekaii-Saab Tanios , Farren Matthew R. , Mace Thomas A. , Schmidt Carl , Liu Yan , Deng Defeng , Hwang Rosa F. , Zhou Liran , Moore Todd , Chatterjee Deyali , Wang Huamin , Leng Xiaohong , Arlinghaus Ralph B. , Logsdon Craig D. , Cruz-Monserrate Zobeida
Published: April 2023

Supplementary Table 1. List of antibodies used for immunohistochemical staining of mouse pancreas.
Supplementary Data from Monocyte Induction of E-Selectin–Mediated Endothelial Activation Releases VE-Cadherin Junctions to Promote Tumor Cell Extravasation in the Metastasis Cascade
Authors: Häuselmann Irina , Roblek Marko , Protsyuk Darya , Huck Volker , Knopfova Lucia , Grässle Sandra , Bauer Alexander T. , Schneider Stefan W. , Borsig Lubor
Published: April 2023

One file of all supplementary data
Supplementary Figures 1 through 9 from SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Authors: Ichihara Eiki , Westover David , Meador Catherine B. , Yan Yingjun , Bauer Joshua A. , Lu Pengcheng , Ye Fei , Kulick Amanda , de Stanchina Elisa , McEwen Robert , Ladanyi Marc , Cross Darren , Pao William , Lovly Christine M.
Published: April 2023

(1) Figure S1. Sustained AKT and MAPK pathway signaling following EGFR TKI treatment in EGFR-mutant lung cancer cells. (2) Figure S2. Analysis of cells treated with TKIs after 96 hours. (3) Figure S3. HER3 reactivation after osimertinib treatment. (4) Figure S4. Combination osimertinib plus SFK inhibitor decreases SFK signaling and results in better cell growth inhibition. (5) Figure S5. Upregulation of SFKs and FAK upon EGFR inhibition in EGFR-mutant lung cancer cells. (6) Figure S6. Osimertinib compared to osimertinib plus dasatinib in an osimertinib-sensitive xenograft model. (7) Figure S7. Extracellular interactions may influence osimertinib potency. (8) Figure S8. SFK/FAK pathway inhibition most potently enhances the effects of osimertinib. (9) Figure S9. Analysis of osimertinib (AZD9291) resistant lung cancer cell lines.
Supplementary Figure Legends and Supplementary Tables 1 and 2 from SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Authors: Ichihara Eiki , Westover David , Meador Catherine B. , Yan Yingjun , Bauer Joshua A. , Lu Pengcheng , Ye Fei , Kulick Amanda , de Stanchina Elisa , McEwen Robert , Ladanyi Marc , Cross Darren , Pao William , Lovly Christine M.
Published: April 2023

This file contains: 1. Supplementary Figure Legends 2. Table S1: EGFR-mutant NSCLC cell lines used in this study. 3. Table S2. Hits from the siRNA screen which potentially attenuate the effects of osimertinib.
Supplementary Figures 1 and 2 from Bronchial Artery Angiogenesis Drives Lung Tumor Growth
Authors: Eldridge Lindsey , Moldobaeva Aigul , Zhong Qiong , Jenkins John , Snyder Michael , Brown Robert H. , Mitzner Wayne , Wagner Elizabeth M.
Published: April 2023

Supplementary Fig 1: Tumor volume determination by high resolution computed tomography (HRCT) scan. Supplementary Fig 2: Quantification of tumor perfusion by contrast enhanced CT imaging.
Supplemental Figures and Tables from Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality
Authors: Eisfeld Ann-Kathrin , Kohlschmidt Jessica , Mrózek Krzysztof , Volinia Stefano , Blachly James S. , Nicolet Deedra , Oakes Christopher , Kroll Karl , Orwick Shelley , Carroll Andrew J. , Stone Richard M. , Byrd John C. , de la Chapelle Albert , Bloomfield Clara D.
Published: April 2023

Supplementary Figure S1. Unsupervised clustering of the sole -7 AML cohort and the complete TCGA AML patient data set. Supplementary Figure S2. SMARCA2 mutations in AML patients with sole -7. Supplementary Figure S3. Heatmap depicting the differential gene expression of AML patients with sole -7. Supplementary Figure S4. Heatmap visualizing the gene ontology (GO) analyses of the predicted target genes of the miRs upregulated in AML patients with sole -7. Supplementary Figure S5. Heatmap visualizing the gene ontology (GO) analyses of the predicted target genes of the miRs downregulated in AML patients with sole -7. Tables: Supplementary Table S1. Gene mutations detected in 36 patients with acute myeloid leukemia (AML) and sole -7 (DNA sequencing of 81 genes). Supplementary Table S2. Mutation analysis in paired germline-leukemic samples of 10 sole -7 patients. Supplementary Table S3. Genes significantly downregulated in 31 AML patients with sole -7 compared with gene expression of 136 AML patients from the TCGA cohort (14) who had other chromosome abnormalities that did not include abnormalities of chromosome 7 or a complex karyotype. Supplementary Table S4. Genes significantly upregulated in 31 AML patients with sole -7 compared with gene expression of 136 AML patients from the TCGA cohort (14) who had other chromosome abnormalities that did not include abnormalities of chromosome 7 or a complex karyotype. Supplementary Table S5. MicroRNAs (miRs) significantly downregulated in 31 AML patients with sole -7 compared with gene expression of 136 AML patients from the TCGA cohort who had other chromosome abnormalities that did not include abnormalities of chromosome 7 or a complex karyotype. Supplementary Table S6. MicroRNAs (miRs) significantly upregulated in 31 AML patients with sole -7 compared with gene expression of 136 AML patients from the TCGA cohort who had other chromosome abnormalities that did not include abnormalities of chromosome 7 or a complex karyotype. Supplementary Table S7. Gene ontogeny analyses of significantly downregulated genes located on chromosome 7 in 31 AML patients with sole -7.
Supplementary Figure Legends from Bronchial Artery Angiogenesis Drives Lung Tumor Growth
Authors: Eldridge Lindsey , Moldobaeva Aigul , Zhong Qiong , Jenkins John , Snyder Michael , Brown Robert H. , Mitzner Wayne , Wagner Elizabeth M.
Published: April 2023

Supplementary Figure Legends
Supplemental Figure Legend for Supplemental Figure 1 from Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer
Authors: Cherkasova Elena , Scrivani Claire , Doh Susan , Weisman Quinn , Takahashi Yoshiyuki , Harashima Nanae , Yokoyama Hisayuki , Srinivasan Ramaprasad , Linehan W. Marston , Lerman Michael I. , Childs Richard W.
Published: April 2023

Supplemental Figure Legend for Supplemental Figure 1
Supplementary Table 1 from Loss of the Methyl-CpG–Binding Protein ZBTB4 Alters Mitotic Checkpoint, Increases Aneuploidy, and Promotes Tumorigenesis
Authors: Roussel-Gervais Audrey , Naciri Ikrame , Kirsh Olivier , Kasprzyk Laetitia , Velasco Guillaume , Grillo Giacomo , Dubus Pierre , Defossez Pierre-Antoine
Published: April 2023

GO terms enriched in Zbtb4 -/- MEFs
Supplementary Figures 1 through 6 from Loss of the Methyl-CpG–Binding Protein ZBTB4 Alters Mitotic Checkpoint, Increases Aneuploidy, and Promotes Tumorigenesis
Authors: Roussel-Gervais Audrey , Naciri Ikrame , Kirsh Olivier , Kasprzyk Laetitia , Velasco Guillaume , Grillo Giacomo , Dubus Pierre , Defossez Pierre-Antoine
Published: April 2023

Figure S1. Controls related to Figure 1. Figure S2. Illustrations and controls related to Figure 2. Figure S3. Controls related to Figure 3. Figure S4. Additional data related to Figure 4. Figure S5. Additional data related to Figure 5. Figure S6. Additional data related to Figure 6.
Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis
Authors: Yuan Peng , He Xiao-Hong , Rong Ye-Fei , Cao Jing , Li Yong , Hu Yun-Ping , Liu Yingbin , Li Dangsheng , Lou Wenhui , Liu Mo-Fang
Published: April 2023

This file contains Materials and Methods that are involved in the figures of the main text and supplementary information. These materials and methods include information of plasmid constructs, cell transfection and viral transduction, RNA preparation and qRT-PCR, luciferase reporter assay, ChIP assay, therapeutic experiments in mice, and immunohistochemistry and in situ hybridization.
Supplemental Figures and table from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis
Authors: Yuan Peng , He Xiao-Hong , Rong Ye-Fei , Cao Jing , Li Yong , Hu Yun-Ping , Liu Yingbin , Li Dangsheng , Lou Wenhui , Liu Mo-Fang
Published: April 2023

This file contains 6 figures (Supplementary Fig. S1-6) and 1 table (Supplementary Table S1). These figures and table provide additional, directly relevant, and unrepeated information for the article content. In brief, Supplementary Figures S1 and S3 indicate that miR-489 is an effector downstream of KRAS signaling; Supplementary Figures S2 and S5 show that miR-489:ADAM9/MMP7 axis doesn't confer the cell proliferation regulation of KRAS signaling; Supplementary Figure S4 highlights the promoting function of ADAM9 and MMP7 in PDAC metastasis; Supplementary Figure S6 is the additional information of Figure 6 in the main text; and Supplementary Table S1 shows the sequences of chemically synthesized DNA and RNA oligonucleotides. These data are equal in quality and presentation to materials within the main article.
Figure S4 from Regeneration of CD8αβ T Cells from T-cell–Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity
Authors: Maeda Takuya , Nagano Seiji , Ichise Hiroshi , Kataoka Keisuke , Yamada Daisuke , Ogawa Seishi , Koseki Haruhiko , Kitawaki Toshio , Kadowaki Norimitsu , Takaori-Kondo Akifumi , Masuda Kyoko , Kawamoto Hiroshi
Published: April 2023

WT1 specific T-iPSCs
Figure S3 from Regeneration of CD8αβ T Cells from T-cell–Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity
Authors: Maeda Takuya , Nagano Seiji , Ichise Hiroshi , Kataoka Keisuke , Yamada Daisuke , Ogawa Seishi , Koseki Haruhiko , Kitawaki Toshio , Kadowaki Norimitsu , Takaori-Kondo Akifumi , Masuda Kyoko , Kawamoto Hiroshi
Published: April 2023

differentiation procedure
Supplementary Table 4 from Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy
Authors: El-Hachem Nehme , Gendoo Deena M.A. , Ghoraie Laleh Soltan , Safikhani Zhaleh , Smirnov Petr , Chung Christina , Deng Kenan , Fang Ailsa , Birkwood Erin , Ho Chantal , Isserlin Ruth , Bader Gary D. , Goldenberg Anna , Haibe-Kains Benjamin
Published: April 2023

Enrichment of DNF drug communities
Figure S1 from Regeneration of CD8αβ T Cells from T-cell–Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity
Authors: Maeda Takuya , Nagano Seiji , Ichise Hiroshi , Kataoka Keisuke , Yamada Daisuke , Ogawa Seishi , Koseki Haruhiko , Kitawaki Toshio , Kadowaki Norimitsu , Takaori-Kondo Akifumi , Masuda Kyoko , Kawamoto Hiroshi
Published: April 2023

SV40 enhance the reprogramming efficiency
Supplementary Figures from Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy
Authors: El-Hachem Nehme , Gendoo Deena M.A. , Ghoraie Laleh Soltan , Safikhani Zhaleh , Smirnov Petr , Chung Christina , Deng Kenan , Fang Ailsa , Birkwood Erin , Ho Chantal , Isserlin Ruth , Bader Gary D. , Goldenberg Anna , Haibe-Kains Benjamin
Published: April 2023

This file contains all the Supplementary Figures (1-9) reporting the results of DNF using the NCI60 drug sensitivity data, as well as additional information regarding the size and distribution for drug communities in the DNF taxonomies
Supplementary Figures 1 through 10 from Activation of NOTCH Signaling by Tenascin-C Promotes Growth of Human Brain Tumor-Initiating Cells
Authors: Sarkar Susobhan , Mirzaei Reza , Zemp Franz J. , Wei Wu , Senger Donna L. , Robbins Stephen M. , Yong V. Wee
Published: April 2023

Supplementary Figure S1:TNC expression in mice implanted with human BTIC. Supplementary Figure S2: TNC expression, BTIC growth and invasiveness in orthotopic BT53M xenograft. Supplementary Figure S3: Tumor growth in orthotopic BTIC 53M xenograft implanted in mice - correspondence of TNC with nucleolin+ areas. Supplementary Figure S4: TNC increases BTIC growth in a concentration dependent manner over time. Supplementary Figure S5: Integrin expression in BTICs and elucidation of the role of alpha2beta1 integrin in TNC promoted BTIC growth. Supplementary Figure S6: Data extraction from Oncomine show elevated JAG1 and NOTCH1 expression in human brain tumors. Supplementary Figure S7: Expression of JAG1 and NOTCH1 is negatively correlated with longevity of patients. Supplementary Figure S8: Correlation between TNC, JAG1, NOTCH1 and alpha2beta1 integrin as determined through the TCGA database. Supplementary Figure S9: Inhibitors, Notch activity and JAG1 expression. Supplementary Figure S10: shRNA to reduce TNC expression in BTICs.
Supplementary Figures and Tables from Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
Authors: Oddo Daniele , Sennott Erin M. , Barault Ludovic , Valtorta Emanuele , Arena Sabrina , Cassingena Andrea , Filiciotto Genny , Marzolla Giulia , Elez Elena , van Geel Robin M.J.M. , Bartolini Alice , Crisafulli Giovanni , Boscaro Valentina , Godfrey Jason T. , Buscarino Michela , Cancelliere Carlotta , Linnebacher Michael , Corti Giorgio , Truini Mauro , Siravegna Giulia , Grasselli Julieta , Gallicchio Margherita , Bernards René , Schellens Jan H.M. , Tabernero Josep , Engelman Jeffrey A. , Sartore-Bianchi Andrea , Bardelli Alberto , Siena Salvatore , Corcoran Ryan B. , Di Nicolantonio Federica
Published: April 2023

Supplementary Tables S1-S3 - List of drug concentrations to generate resistant cell lines (S1); Drug concentrations applied in the screening depicted in Figure 6 (S2); Primers for gene amplification and sequencing (S3). Supplementary Figure S1. Synergistic activity of targeted therapy combinations in BRAF mutant colorectal cancer cells. Supplementary Figure S2. Amplification of mutant BRAF V600E confers resistance to combined EGFR and MEK targeting in colorectal cancer cells. Supplemental Figure S3. Cytotoxicity induced by ERK inhibition in VACO432 resistant to BRAF combination therapies.
Supplementary Figure Legends from Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer
Authors: Oddo Daniele , Sennott Erin M. , Barault Ludovic , Valtorta Emanuele , Arena Sabrina , Cassingena Andrea , Filiciotto Genny , Marzolla Giulia , Elez Elena , van Geel Robin M.J.M. , Bartolini Alice , Crisafulli Giovanni , Boscaro Valentina , Godfrey Jason T. , Buscarino Michela , Cancelliere Carlotta , Linnebacher Michael , Corti Giorgio , Truini Mauro , Siravegna Giulia , Grasselli Julieta , Gallicchio Margherita , Bernards René , Schellens Jan H.M. , Tabernero Josep , Engelman Jeffrey A. , Sartore-Bianchi Andrea , Bardelli Alberto , Siena Salvatore , Corcoran Ryan B. , Di Nicolantonio Federica
Published: April 2023

Legends
Supplementary Table 2 from Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation
Authors: Schwartz Hila , Blacher Eran , Amer Malak , Livneh Nir , Abramovitz Lilach , Klein Anat , Ben-Shushan Dikla , Soffer Shelly , Blazquez Raquel , Barrantes-Freer Alonso , Müller Meike , Müller-Decker Karin , Stein Reuven , Tsarfaty Galia , Satchi-Fainaro Ronit , Umansky Viktor , Pukrop Tobias , Erez Neta
Published: April 2023

Incidence of spontaneous micrometastases
supplementary Tables 1 through 5 from Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer
Authors: Xing Fei , Liu Yin , Sharma Sambad , Wu Kerui , Chan Michael D. , Lo Hui-Wen , Carpenter Richard L. , Metheny-Barlow Linda J. , Zhou Xiaobo , Qasem Shadi A. , Pasche Boris , Watabe Kounosuke
Published: April 2023

Supplementary Table S1: Pathways that used in GSEA. Supplementary Table S2: Clinical information of the 715 breast cancer patients. Supplementary Table S3: Summary of enriched pathways in patients with or without brain metastases. Supplementary Table S4: GSEA results of natural compounds which are associated with brain metastasis status. Supplementary Table S5: Fold change of top down regulated adhesion genes between two groups that with or without knock down of c-Met by doxycycline.
Supplementary Materials and Methods from Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation
Authors: Schwartz Hila , Blacher Eran , Amer Malak , Livneh Nir , Abramovitz Lilach , Klein Anat , Ben-Shushan Dikla , Soffer Shelly , Blazquez Raquel , Barrantes-Freer Alonso , Müller Meike , Müller-Decker Karin , Stein Reuven , Tsarfaty Galia , Satchi-Fainaro Ronit , Umansky Viktor , Pukrop Tobias , Erez Neta
Published: April 2023

Supplementary Methods
Supplementary Figures 1 through 7 from Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer
Authors: Xing Fei , Liu Yin , Sharma Sambad , Wu Kerui , Chan Michael D. , Lo Hui-Wen , Carpenter Richard L. , Metheny-Barlow Linda J. , Zhou Xiaobo , Qasem Shadi A. , Pasche Boris , Watabe Kounosuke
Published: April 2023

Supplementary Figure S1. GSEA results of selected pathways. Supplementary Figure S2. c-Met expression in clinical samples and brain metastatic cells. Supplementary Figure S3. Knockdown of c-Met suppresses IL1beta, IL8 and CXCL1 expressions in brain metastatic cells. Supplementary Figure S4. c-Met signaling induces IL1β, IL8 and CXCL1. Supplementary Figure S5. MTS assay of HBMEC. Supplementary Figure S6. Activation of tumor associated astrocytes by tumor cells. Supplementary Figure S7. PTER suppresses brain metastasis by targeting c-Met induced inflammation.
Supplementary Figure S7 from Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation
Authors: Schwartz Hila , Blacher Eran , Amer Malak , Livneh Nir , Abramovitz Lilach , Klein Anat , Ben-Shushan Dikla , Soffer Shelly , Blazquez Raquel , Barrantes-Freer Alonso , Müller Meike , Müller-Decker Karin , Stein Reuven , Tsarfaty Galia , Satchi-Fainaro Ronit , Umansky Viktor , Pukrop Tobias , Erez Neta
Published: April 2023

Supplementary Figure S7: Brain tropic melanoma cells (BT-RMS) have a more aggressive phenotype
Figure S4. BRD4 and JAG1 expression correlate with disseminated human breast cancer in vivo. from BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling
Authors: Andrieu Guillaume , Tran Anna H. , Strissel Katherine J. , Denis Gerald V.
Published: April 2023

Kaplan-Meier curve to plot distant metastasis-free survival of 664 breast cancer patients was calculated from the Kaplan-Meier plotter database. Patients were subdivided into 'high expression' (BRD4high, JAG1high, n=332) and 'low expression' (BRD4low, JAG1low, n=332) groups of equal size, based on median expression of BRD4 and JAG1. Hazard ratio, 95% confidence interval (CI) and p value are indicated. The number of patients at risk is also indicated.
Supplementary Figure S3 from Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation
Authors: Schwartz Hila , Blacher Eran , Amer Malak , Livneh Nir , Abramovitz Lilach , Klein Anat , Ben-Shushan Dikla , Soffer Shelly , Blazquez Raquel , Barrantes-Freer Alonso , Müller Meike , Müller-Decker Karin , Stein Reuven , Tsarfaty Galia , Satchi-Fainaro Ronit , Umansky Viktor , Pukrop Tobias , Erez Neta
Published: April 2023

Supplementary Figure S3: FACS analysis enables the detection and quantification of brain micrometastases
Figure S3. Jagged1 function in SUM149PT cells from BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling
Authors: Andrieu Guillaume , Tran Anna H. , Strissel Katherine J. , Denis Gerald V.
Published: April 2023

(A) Heatmap representing relative expression of 46 genes involved in regulation of migration and invasion in response to BRD4 depletion in SUM149PT cells. Z scores are represented using a color code. Results for separate knockdown experiments were considered (n = 3). (B-C) Jagged1 mRNA (A) and protein (B) expression were measured in SUM149PT cells 72h after transfection with the indicated siRNAs (50 nM). Statistical analyses were performed by using one-way ANOVA. (D) Migration (left panel) and invasion (right panel) assays were conducted with scramble or Jagged1-depleted SUM149PT cells. Bars show means {plus minus} SEM of three independent experiments. Statistical analyses were performed by using Student's t test. Bottom panel: immunoblot validated Jagged1 depletion in SUM149PT 48h after transfection with the indicated siRNAs (20 nM).
Figure S2. BET protein specificity and proliferation/survival from BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling
Authors: Andrieu Guillaume , Tran Anna H. , Strissel Katherine J. , Denis Gerald V.
Published: April 2023

(A-C) Relative mRNA expression levels of BRD2 (A), BRD3 (B), and BRD4 (C) in scrambled siRNA control or BRD2-, BRD3-, BRD4-depleted MDA-MB-231 cells. Bars show means (plus minus) SEM of three independent experiments. Statistical analyses were performed by using one-way ANOVA. (D) Dotplot of Annexin V/propidium iodide co-staining of MDA-MB-231 and SUM149PT cells treated with scramble, siBRD2, siBRD3 or BRD4 siRNA for 72h. Quadrant 1 (Q1): necrotic cells, Q2: late apoptotic cells, Q3: early apoptotic cells, Q4: viable cells. At least 20,000 cells were analyzed (n=3). (E) Cell cycle distribution of MDA-MB-231 and SUM149PT treated with scrambled siRNA control, siBRD2, siBRD3 or siBRD4 for 72h. At least 10,000 cells were analyzed (n=3). (F) MTT assay showing proliferation of MDA-MB-231, SUM149PT and MCF-7 treated with scramble, siBRD2, siBRD3 or BRD4 siRNA for 72h for the indicated times. Bars represent means (plus minus) SEM of three independent experiments. Statistical analysis was performed by using two-way ANOVA.
Table S1 from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Authors: Kosaka Takayuki , Tanizaki Junko , Paranal Raymond M. , Endoh Hideki , Lydon Christine , Capelletti Marzia , Repellin Claire E. , Choi Jihyun , Ogino Atsuko , Calles Antonio , Ercan Dalia , Redig Amanda J. , Bahcall Magda , Oxnard Geoffrey R. , Eck Michael J. , Jänne Pasi A.
Published: April 2023

Supplemental Table 1.
All supplemental Figures from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Authors: Kosaka Takayuki , Tanizaki Junko , Paranal Raymond M. , Endoh Hideki , Lydon Christine , Capelletti Marzia , Repellin Claire E. , Choi Jihyun , Ogino Atsuko , Calles Antonio , Ercan Dalia , Redig Amanda J. , Bahcall Magda , Oxnard Geoffrey R. , Eck Michael J. , Jänne Pasi A.
Published: April 2023

Figure S1. Fifty percent (50%) inhibitory concentration of neratinib, afatinib and dacomitinib in Ba/F3 cells expressing different EGFR or HER2 exon 20 insertion mutations and the EGFR exon 20 insertion patient derived cell lines. to second generation EGFR-TKIs; Figure S2. Efficacy of neratinib, afatinib or dacomitinib against HER2 exon 20 insertion mutants measured in a soft agar assay; Figure S3. Patient derived EGFR exon 20 insertion cell lines; Figure S4. Comparison of amino acid sequences of exon 20 of EGFR to HER2.
Table S1 from Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer
Authors: Safonov Anton , Jiang Tingting , Bianchini Giampaolo , Győrffy Balázs , Karn Thomas , Hatzis Christos , Pusztai Lajos
Published: April 2023

Clinical annotation of each sample included in the analysis and corresponding LCK metagene expression levels.
Supplementary Figure S4 from miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
Authors: D'Ippolito Elvira , Plantamura Ilaria , Bongiovanni Lucia , Casalini Patrizia , Baroni Sara , Piovan Claudia , Orlandi Rosaria , Gualeni Ambra V. , Gloghini Annunziata , Rossini Anna , Cresta Sara , Tessari Anna , De Braud Filippo , Di Leva Gianpiero , Tripodo Claudio , Iorio Marilena V.
Published: April 2023

Supplementary Figure S4. PDGFRbeta identifies vascular lacunae in TNBC tissues
Supplementary Figure S3 from miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
Authors: D'Ippolito Elvira , Plantamura Ilaria , Bongiovanni Lucia , Casalini Patrizia , Baroni Sara , Piovan Claudia , Orlandi Rosaria , Gualeni Ambra V. , Gloghini Annunziata , Rossini Anna , Cresta Sara , Tessari Anna , De Braud Filippo , Di Leva Gianpiero , Tripodo Claudio , Iorio Marilena V.
Published: April 2023

MiR-200 family inhibits tube formation ability through PDGFRbeta repression
Supplementary Figure S2 from miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer
Authors: D'Ippolito Elvira , Plantamura Ilaria , Bongiovanni Lucia , Casalini Patrizia , Baroni Sara , Piovan Claudia , Orlandi Rosaria , Gualeni Ambra V. , Gloghini Annunziata , Rossini Anna , Cresta Sara , Tessari Anna , De Braud Filippo , Di Leva Gianpiero , Tripodo Claudio , Iorio Marilena V.
Published: April 2023

MiR-9 is higher in TNBC and associates with poor prognosis in breast cancer
Supplemental Table 1-9 and supplemental Figure 1-12 from Long Noncoding RNA GCASPC, a Target of miR-17-3p, Negatively Regulates Pyruvate Carboxylase–Dependent Cell Proliferation in Gallbladder Cancer
Authors: Ma Ming-zhe , Zhang Yan , Weng Ming-zhe , Wang Shou-hua , Hu Ye , Hou Zhao-yuan , Qin Yi-yu , Gong Wei , Zhang Yong-Jie , Kong Xiang , Wang Jian-dong , Quan Zhi-wei
Published: April 2023

Supplemental Table 1-9. Clinical characteristics of 5 GBC patients used for lncRNA array (Table 1). Clinicopathological characterisitcs of 42 GBC patients (Cohort 1) (Table 2). Clinicopathological characterisitcs of 89 GBC patients (Cohort 2) (Table 3). Correlation between GCASPC expression and GBC clinicopathological characteristics in 42 patients (Cohort 1) (Table 4). Univariate and multivariate analyses of OS in 89 GBC patients by Cox regression analysis (Table 5). Proteins in the three bands specific to GCASPC identified by MALDI-TOF mass spectrometry (Table 6). miRNAs binding sites of GCASPC by MirTarget2 (Table 7). Information on antibodies used for correlation analysis (Table 8). Primer sequence used in this study (Table 9). supplemental Figure 1-12. Expression levels of 10 lncRNAs by qRT-PCR in 15 GBC tissues and paired non-tumor tissues (Figure 1). Expression levels of 8 mRNAs by qRT-PCR in 15 GBC tissues and paired non-tumor tissues (Figure 2). Molecular characteristics of GCASPC (Figure 3). Nucleotide sequence of the full-length human GCASPC gene (Figure 4). GCASPC has no coding capability (Figure 5). The expression level of GCASPC in gallbladder cancer cells (Figure 6). Manipulation of GCASPC expression level (Figure 7). Anti-proliferative activity of GCASPC (Figure 8). GCASPC acts in trans (Figure 9). The effect of GCASPC on the protein, activity and mRNA levels of PC (Figure 10). GCASPC destabilizes PC protein (Figure 11). GCASPC directly binds to miR-17-3p (Figure 12).
Supplementary Methods from Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses
Authors: Karpel-Massler Georg , Ishida Chiaki Tsuge , Bianchetti Elena , Shu Chang , Perez-Lorenzo Rolando , Horst Basil , Banu Matei , Roth Kevin A. , Bruce Jeffrey N. , Canoll Peter , Altieri Dario C. , Siegelin Markus D.
Published: April 2023

Supplementary Methods
Table S6 from Western Diet Deregulates Bile Acid Homeostasis, Cell Proliferation, and Tumorigenesis in Colon
Authors: Dermadi Denis , Valo Satu , Ollila Saara , Soliymani Rabah , Sipari Nina , Pussila Marjaana , Sarantaus Laura , Linden Jere , Baumann Marc , Nyström Minna
Published: April 2023

Table S6. LC-MS analysis: Abundance matrix and fold changes between different experimental groups
Supplementary Data and Legends from Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses
Authors: Karpel-Massler Georg , Ishida Chiaki Tsuge , Bianchetti Elena , Shu Chang , Perez-Lorenzo Rolando , Horst Basil , Banu Matei , Roth Kevin A. , Bruce Jeffrey N. , Canoll Peter , Altieri Dario C. , Siegelin Markus D.
Published: April 2023

Supplementary Figures and Tables: Legend
Table S4 from Western Diet Deregulates Bile Acid Homeostasis, Cell Proliferation, and Tumorigenesis in Colon
Authors: Dermadi Denis , Valo Satu , Ollila Saara , Soliymani Rabah , Sipari Nina , Pussila Marjaana , Sarantaus Laura , Linden Jere , Baumann Marc , Nyström Minna
Published: April 2023

Table S4. 2D DIGE analysis: Fold changes between different experimental groups
Supplementary Table S1 from Enhanced Detection of Cancer Biomarkers in Blood-Borne Extracellular Vesicles Using Nanodroplets and Focused Ultrasound
Authors: Paproski Robert J. , Jovel Juan , Wong Gane Ka-Shu , Lewis John D. , Zemp Roger J.
Published: April 2023

Thirteen heterozygous mutations specific to HT1080 cells detected in the serum of chicken embryos with sonicated HT1080-GFP tumors.
Table S3 from Western Diet Deregulates Bile Acid Homeostasis, Cell Proliferation, and Tumorigenesis in Colon
Authors: Dermadi Denis , Valo Satu , Ollila Saara , Soliymani Rabah , Sipari Nina , Pussila Marjaana , Sarantaus Laura , Linden Jere , Baumann Marc , Nyström Minna
Published: April 2023

Table S3. Mass spectrometry scores, coverage and peptide sequences used for protein identification
Supplementary Materials and Methods from Enhanced Detection of Cancer Biomarkers in Blood-Borne Extracellular Vesicles Using Nanodroplets and Focused Ultrasound
Authors: Paproski Robert J. , Jovel Juan , Wong Gane Ka-Shu , Lewis John D. , Zemp Roger J.
Published: April 2023

Additional information on the experimental procedures used in the study.
Supplementary Figure S4 from Enhanced Detection of Cancer Biomarkers in Blood-Borne Extracellular Vesicles Using Nanodroplets and Focused Ultrasound
Authors: Paproski Robert J. , Jovel Juan , Wong Gane Ka-Shu , Lewis John D. , Zemp Roger J.
Published: April 2023

Comparing ultrasound parameters and size of released extracellular vesicles.
Supplementary Figure S2 from Enhanced Detection of Cancer Biomarkers in Blood-Borne Extracellular Vesicles Using Nanodroplets and Focused Ultrasound
Authors: Paproski Robert J. , Jovel Juan , Wong Gane Ka-Shu , Lewis John D. , Zemp Roger J.
Published: April 2023

Microscopy analysis of microbubbles in ultrasound contrast solutions including 4% (v/v) microbubbles, nanodroplets, and sucrose-purified nanodroplets.
Supplementary Figure S1 from Enhanced Detection of Cancer Biomarkers in Blood-Borne Extracellular Vesicles Using Nanodroplets and Focused Ultrasound
Authors: Paproski Robert J. , Jovel Juan , Wong Gane Ka-Shu , Lewis John D. , Zemp Roger J.
Published: April 2023

Characterization of nanodroplets used for promoting ultrasound-mediated vesicle release.
Supplementary Figure 4 from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature
Authors: Gilles Maud-Emmanuelle , Maione Federica , Cossutta Mélissande , Carpentier Gilles , Caruana Laure , Di Maria Silvia , Houppe Claire , Destouches Damien , Shchors Ksenya , Prochasson Christopher , Mongelard Fabien , Lamba Simona , Bardelli Alberto , Bouvet Philippe , Couvelard Anne , Courty José , Giraudo Enrico , Cascone Ilaria
Published: April 2023

Stroma NCL inhibition increases pericyte coverage of tumor blood vessels.
Supplementary Materials and Methods from Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer
Authors: Rucki Agnieszka A. , Foley Kelly , Zhang Pingbo , Xiao Qian , Kleponis Jennifer , Wu Annie A. , Sharma Rajni , Mo Guanglan , Liu Angen , Van Eyk Jennifer , Jaffee Elizabeth M. , Zheng Lei
Published: April 2023

This file includes: 1. Sequences of primers for quantitative real time RT-PCR 2. Sequences of peptides for multiple reaction monitoring 3. Immunohistochemistry Instrumentation Settings 4. Cell proliferation assays (Supplementary Fig. S4)
Supplementary Figure 2 from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature
Authors: Gilles Maud-Emmanuelle , Maione Federica , Cossutta Mélissande , Carpentier Gilles , Caruana Laure , Di Maria Silvia , Houppe Claire , Destouches Damien , Shchors Ksenya , Prochasson Christopher , Mongelard Fabien , Lamba Simona , Bardelli Alberto , Bouvet Philippe , Couvelard Anne , Courty José , Giraudo Enrico , Cascone Ilaria
Published: April 2023

NCL blocking antibody and Ncl deletion affects PDAC cell proliferation.
Supplementary Figure 1 from Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature
Authors: Gilles Maud-Emmanuelle , Maione Federica , Cossutta Mélissande , Carpentier Gilles , Caruana Laure , Di Maria Silvia , Houppe Claire , Destouches Damien , Shchors Ksenya , Prochasson Christopher , Mongelard Fabien , Lamba Simona , Bardelli Alberto , Bouvet Philippe , Couvelard Anne , Courty José , Giraudo Enrico , Cascone Ilaria
Published: April 2023

N6L inhibits PDAC proliferation and migration
Supplemental Table 3 from Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis
Authors: Murphy Brendan , Yin Han , Maris John M. , Kolb E. Anders , Gorlick Richard , Reynolds C. Patrick , Kang Min H. , Keir Stephen T. , Kurmasheva Raushan T. , Dvorchik Igor , Wu Jianrong , Billups Catherine A. , Boateng Nana , Smith Malcolm A. , Lock Richard B. , Houghton Peter J.
Published: April 2023

Means and variances of variances for single mouse response in each group cross the studies for best and worst models.
Table S1 from SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells
Authors: Redd Priscilla S. , Ibrahim Mohammed L. , Klement John D. , Sharman Sarah K. , Paschall Amy V. , Yang Dafeng , Nayak-Kapoor Asha , Liu Kebin
Published: April 2023

Table S1 contains oligonucleotide sequences
Figure S2 from SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells
Authors: Redd Priscilla S. , Ibrahim Mohammed L. , Klement John D. , Sharman Sarah K. , Paschall Amy V. , Yang Dafeng , Nayak-Kapoor Asha , Liu Kebin
Published: April 2023

Figure S2 shows SETD1B expression level in human MDSCs
Supplemental Table 1 from Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis
Authors: Murphy Brendan , Yin Han , Maris John M. , Kolb E. Anders , Gorlick Richard , Reynolds C. Patrick , Kang Min H. , Keir Stephen T. , Kurmasheva Raushan T. , Dvorchik Igor , Wu Jianrong , Billups Catherine A. , Boateng Nana , Smith Malcolm A. , Lock Richard B. , Houghton Peter J.
Published: April 2023

Identity and mechanism of action of 67 agents tested
Figure S1 from SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells
Authors: Redd Priscilla S. , Ibrahim Mohammed L. , Klement John D. , Sharman Sarah K. , Paschall Amy V. , Yang Dafeng , Nayak-Kapoor Asha , Liu Kebin
Published: April 2023

Figure S1 shows MDSC profiles in chaetocin-treated tumor-bearing mice
Supplemental Materials and Methods from FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Authors: Traer Elie , Martinez Jacqueline , Javidi-Sharifi Nathalie , Agarwal Anupriya , Dunlap Jennifer , English Isabel , Kovacsovics Tibor , Tyner Jeffrey W. , Wong Melissa , Druker Brian J.
Published: April 2023

Supplementary materials and methods.
Supplementary Table and Figure Legend from Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma
Authors: Lamy Philippe , Nordentoft Iver , Birkenkamp-Demtröder Karin , Thomsen Mathilde Borg Houlberg , Villesen Palle , Vang Søren , Hedegaard Jakob , Borre Michael , Jensen Jørgen Bjerggaard , Høyer Søren , Pedersen Jakob Skou , Ørntoft Torben F. , Dyrskjøt Lars
Published: April 2023

Legend for Supplementary Tables S1-S6 and Supplementary Figures S1-S19.
Supplemental Figures from FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Authors: Traer Elie , Martinez Jacqueline , Javidi-Sharifi Nathalie , Agarwal Anupriya , Dunlap Jennifer , English Isabel , Kovacsovics Tibor , Tyner Jeffrey W. , Wong Melissa , Druker Brian J.
Published: April 2023

Figure S1. FGFR1 is the most highly expressed FGFR in MOLM 14 and siRNA knock down of FGFR mRNA. Figure S2. FGF2 protection from FLT3 inhibitors is dependent upon FGFR expression. Figure S3. Matrix of AC220 and PD173074. Figure S4. STAT5 and ERK are downstream targets of FLT3. Figure S5. Resistant long-term cultures have very similar phosphorylated proteins to naïve MOLM14 cells. Figure S6. Identification of FLT3 point mutations by Sanger sequencing. Figure S7. Removing FL or FGF2 from resistant cultures results in partial reactivation of FLT3 either through point mutation or non-mutational activation. Figure S8. FGF2 is localized to bone marrow stromal cells and not in hematopoietic cells. Figure S9. FGFR1 and FLT3 do not interact directly. Figure S10. FGF2- and FL-mediated resistance has restoration of pSYK.
Supplementary Table S6 from Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma
Authors: Lamy Philippe , Nordentoft Iver , Birkenkamp-Demtröder Karin , Thomsen Mathilde Borg Houlberg , Villesen Palle , Vang Søren , Hedegaard Jakob , Borre Michael , Jensen Jørgen Bjerggaard , Høyer Søren , Pedersen Jakob Skou , Ørntoft Torben F. , Dyrskjøt Lars
Published: April 2023

Potential therapeutic targets.
Supplemental Figure Legends from FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Authors: Traer Elie , Martinez Jacqueline , Javidi-Sharifi Nathalie , Agarwal Anupriya , Dunlap Jennifer , English Isabel , Kovacsovics Tibor , Tyner Jeffrey W. , Wong Melissa , Druker Brian J.
Published: April 2023

This file contains the legends for Supplemental Figures 1-10.
Supplementary Table S4 from Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma
Authors: Lamy Philippe , Nordentoft Iver , Birkenkamp-Demtröder Karin , Thomsen Mathilde Borg Houlberg , Villesen Palle , Vang Søren , Hedegaard Jakob , Borre Michael , Jensen Jørgen Bjerggaard , Høyer Søren , Pedersen Jakob Skou , Ørntoft Torben F. , Dyrskjøt Lars
Published: April 2023

Heat maps of mutations and gene expression for patients with three or more tumor sample analyzed.
Combined supplemental figures 1-7 from Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
Authors: Clark Curtis A. , Gupta Harshita B. , Sareddy Gangadhara , Pandeswara Srilakshmi , Lao Shunhua , Yuan Bin , Drerup Justin M. , Padron Alvaro , Conejo-Garcia José , Murthy Kruthi , Liu Yang , Turk Mary Jo , Thedieck Kathrin , Hurez Vincent , Li Rong , Vadlamudi Ratna , Curiel Tyler J.
Published: April 2023

Suppl. Fig. 1 confirms that ID8agg is more virulent versus parental ID8 in WT mice. Suppl. Fig. 2 provides relevant details for plasmids used to make recombinant cell lines, and gives Western blot validations for each PD-L1lo clone described. Suppl, Fig. 3 shows that αPD-L1 reduces tumor growth and metastatic spread of B16hi cells in NSG mice and shows color photomicrographs of lungs from treated mice. Suppl. Fig. 4 shows that αPD-L1 immunotherapy fails to treat ID8agg in wild-type mice. Suppl. Fig. 5 shows that tumor PD-L1 is necessary and sufficient for αPD-L1 treatment effects on B16 cells challenged into wild type mice. Suppl. Fig. 6 provides much additional Western blot data on mTORC1 and mTORC2 signals in B16 and ID8agg cells after rapamycin or chloroquine treatments. Suppl. Fig. 7 shows effects of tumor cell PD-L1 expression on B16 and ID8agg cell proliferation sensitivity to TNFα, cis-platinum and paclitaxel in vitro.